Close

SAGE and BIIB Related Headlines

Go Back

Aug 7, 2023 10:12AM Stifel Downgrades Sage Therapeutics (SAGE) to Hold, 'we think Biogen is unlikely to buy Sage outright '
Aug 7, 2023 07:04AM Sage, Biogen receive setback despite FDA approval of postpartum depression drug. This is why
Aug 7, 2023 06:24AM SAGE Therapeutics (SAGE), Biogen (BIIB) ZURZUVAETM approved in PPD, receives CRL for MDD
Aug 4, 2023 10:42PM FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Mar 8, 2023 06:30AM Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
Feb 6, 2023 06:51AM Biogen (BIIB), Sage Therapeutics (SAGE) announce FDA acceptance of NDA for zuranolone to treat MDD and PPD
Feb 6, 2023 06:30AM Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Feb 6, 2023 06:30AM Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Feb 6, 2023 06:30AM Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Dec 6, 2022 06:30AM Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

SAGE and BIIB Related Press Releases

Go Back

Aug 4, 2023 10:42PM FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Mar 8, 2023 06:30AM Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
Feb 6, 2023 06:30AM Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Feb 6, 2023 06:30AM Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Feb 6, 2023 06:30AM Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Dec 6, 2022 06:30AM Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

SAGE and BIIB Related SEC Filings

Go Back